The comparative effects of pioglitazone and rosiglitazone on lipoprotein sub-fractions in patients with type 2 diabetes and dyslipidemia

被引：0
|
作者：
Deeg, MA
Goldberg, RB
Buse, JB
Kendall, DM
Zagar, AJ
Pinaire, JA
Tan, MH
Khan, MA
Perez, AT
Jacober, SJ
机构：
来源：
DIABETES | 2005年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A234 / A235
页数：2
相关论文
共 50 条
  • [41] Favorable effects of pioglitazone and metformin compared with gliclazoide on lipoprotein subfractions in overweight patients with early type 2 diabetes
    Lawrence, JM
    Reid, J
    Taylor, GJ
    Stirling, C
    Recklees, JPD
    [J]. DIABETES CARE, 2004, 27 (01) : 41 - 46
  • [42] Rosiglitazone and Pioglitazone Have Opposite Effects on Skeletal Muscle Mitochondrial Content and Function in Type 2 Diabetes
    Rabol, Rasmus
    Boushel, Robert
    Almdal, Thomas
    Ploug, Thorkil
    Haugaard, Steen B.
    Madsbad, Sten
    Dela, Flemming
    [J]. DIABETES, 2009, 58 : A67 - A67
  • [43] A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone
    Khan, MA
    StPeter, JV
    Xue, JL
    [J]. DIABETES CARE, 2002, 25 (04) : 708 - 711
  • [44] Effect of Alogliptin Combined With Pioglitazone on Lipids and Lipoprotein Particles in Patients With Type 2 Diabetes
    Fleck, Penny
    Wilson, Craig
    [J]. DIABETES, 2012, 61 : A300 - A300
  • [45] A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes
    Gerrits, Charles M.
    Bhattacharya, Mondira
    Manthena, Shivaji
    Baran, Robert
    Perez, Alfonso
    Kupfer, Stuart
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (12) : 1314 - 1316
  • [46] Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes
    Aubert, R. E.
    Herrera, V.
    Chen, W.
    Haffner, S. M.
    Pendergrass, M.
    [J]. DIABETES OBESITY & METABOLISM, 2010, 12 (08): : 716 - 721
  • [47] Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin
    Derosa, G.
    D'Angelo, A.
    Ragonesi, P. D.
    Ciccarelli, L.
    Piccinni, M. N.
    Pricolo, F.
    Salvadeo, S. A. T.
    Montagna, L.
    Gravina, A.
    Ferrari, I.
    Paniga, S.
    Cicero, A. F. G.
    [J]. INTERNAL MEDICINE JOURNAL, 2007, 37 (02) : 79 - 86
  • [48] Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: A cross-sectional, observational pilot study
    Gul, Ozen Oz
    Cinkilic, Nilufer
    Gul, Cuma Bulent
    Cander, Soner
    Vatan, Ozgur
    Ersoy, Canan
    Yilmaz, Dilek
    Tuncel, Ercan
    [J]. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2013, 757 (01) : 31 - 35
  • [49] Dyslipidemia in Type-2-Diabetes: Pioglitazone shows significant Lipid Benefit
    Tatschl, Christian
    [J]. JOURNAL FUR KARDIOLOGIE, 2005, 12 (9-10): : 272 - 274
  • [50] The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus
    Park, Jong Suk
    Cho, Min Ho
    Lee, Kyung Yul
    Kim, Chul Sik
    Kim, Hai Jin
    Nam, Ji Sun
    Ahn, Chul Woo
    Cha, Bong Soo
    Lim, Sung Kil
    Kim, Kyung Rae
    Lee, Hyun Chul
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2007, 56 (08): : 1081 - 1086
12345